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Abstract
Background: Surgical excision is the primary treatment for a thymoma. However, for advanced thymoma that
extends to within the thoracic cavity and for recurrent cases with pleural dissemination (Masaoka stage IVA), the
appropriate treatment is controversial. We evaluated the safety of surgery and outcomes of seven patients that
underwent an en bloc extended total thymectomy and extrapleural pneumonectomy for stage IVA thymomas.
Methods: From 1994 to 2009, five patients initially diagnosed with pleural dissemination and two patients with
recurrent tumors in the pleura and lungs after a total thymectomy, were identified. Seven patients had an
extrapleural pneumonectomy performed. For the first operation, five patients underwent additional en bloc
extended total thymectomy.
Results: Two recurrent cases were identified 55.2 and 12.3 months after first operation. Two patients had WHO
type B1-B2 tumors, two had B2, two had B2-B3, and one had a B3 tumor. The mean hospital stay was 15.3 days
(range: 7-29). There was no operative mortality. Four patients had neoadjuvant chemotherapy and five were
treated with adjuvant chemotherapy. The median survival was 30.6 months and the Kaplan-Meier 2-year survival
was 100% (95% confidence interval: 24.6-36.6 months). One patient, who did not receive induction chemotherapy,
had distant metastases after surgery.
Conclusions: En bloc extended total thymectomy and extrapleural pneumonectomy can be safely performed on
selected patients with stage IVA thymomas and is expected to achieve complete local control. Although the
treatment strategy has yet to be standardized, complete resection with appropriate systemic therapy may improve
survival in otherwise fatal disease.
Background
The prognosis of locally advanced thymomas within the
thoracic cavity (Masaoka stage IVA) is poor [1-3]; there
is no reliable treatment strategy established to date [4,5].
All three common therapeutic modalities (surgery, che-
motherapy and radiation) can be used for the treatment
of locally advanced thymoma [6,7]. However, the combi-
nation of these modalities has not been standardized.
Complete local control is the mainstay of treatment
for a thymoma; this is because thymomas rarely
metastasize to distant organs. For stage IVA thymomas,
the tumor has not yet spread to extrathoracic organs
and is still locally advanced. This stage allows for com-
plete eradication. However, in miliary or confluent
pleural disseminated thymomas, complete resection is
almost impossible with a simple pleurectomy. In these
cases, only extrapleural pneumonectomy (EPP) can
resect all gross implants. EPP has also been performed
in other malignant pleural tumors such as mesothelio-
mas. The aim of this retrospective study was to evaluate
the safety and the long term efficacy of en bloc extended
total thymectomy and EPP procedures for stage IVA
thymomas. * Correspondence: jkimsmc@skku.edu
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A retrospective review of all patients undergoing resec-
tion for thymic epithelial tumors, at a single center
between January 1994 and December 2009, was per-
formed. During this time period, 335 patients underwent
surgery for the treatment of a thymoma. There were 19
patients (5.7%) diagnosed with stage IVA thymomas.
Simple parietal pleurectomy and resection of the
involved lung were performed in seven patients, debulk-
ing surgery in two, and biopsy only in three. Seven con-
secutive patients (2.1%) underwent EPP for Masaoka
stage IVA thymomas and were included in this analysis.
The patient characteristics are listed in Table 1.
Among the seven patients, patient 2 and 3 were trea-
ted for a recurrent thymoma in the pleural cavity. The
other five patients that initially presented with a med-
iastinal thymoma and pleural dissemination, underwent
an en bloc extended total thymectomy and EPP.
None of the patients had extrathoracic metastatic dis-
ease by the whole body positron emission tomography -
computed tomography (PET-CT). All patients were
t h o u g h tt ob ea b l et ot o l e r a t et h ep n e u m o n e c t o m yi n
terms of heart and lung function. There were no other
significant medical problems such as myasthenia gravis.
EPP was performed by thoracotomy; pericardial recon-
struction with a bovine pericardium and reconstruction
of the diaphragm with a polytetrafluoroethylene (PTFE)
patch was carried out. Patients 1, 4 and 6 underwent an
en bloc extended total thymectomy and EPP by thora-
cotomy only. In two cases (patient 5 and 7) with inva-
sion of the innominate vein, a median sternotomy was
added for en bloc extended total thymectomy immedi-
ately after resecting the lungs and pleura via a postero-
lateral thoracotomy. Complete resection was defined as
resection of all gross tumors with negative margins on
pathology. Our institutional review board granted
approval for this study on April 22, 2010.
Af o l l o wu pc o m p u t e dt o m o g r a p h y( C T )o ft h ec h e s t
was obtained at three and six months after surgery and
then a PET-CT was performed at 12 months. One year
after the operation, a chest CT was performed every 6
months and PET-CT every 12-18 months in the
absence of changes in the clinical condition. The date
of recurrence was determined from the first postopera-
tive radiological images that showed evidence of recur-
rence. Survival was calculated from the date of the
operation to the date of death or to the date of the last
follow up and was estimated by the Kaplan-Meier
method using SPSS 17.0 (SPSS Inc, Chicago, Ill)
software.
Results
The median patient age was 50 (range: 34-65 years).
Four patients were male. There were right pleural
lesions in four cases. Mean operative time was 431 ± 61
minutes (range: 372-533 minutes) and bleeding loss dur-
ing the procedure was mean 1210 ± 561 cc. There was
no operative mortality and no additional morbidity
except for one patient with postoperative delirium. All
patients were discharged from the hospital without any
significant problems. The mean postoperative hospital
stay was 15 days (range: 7-29 days).
According to the pathology report, two patients had
WHO type B1-B2 tumors, two had B2, two had B2-B3,
and one had a B3 tumor. The mean of the largest mass
was 9.9 cm (range: 6-13 cm). None of the patients had
lymph node metastasis. Complete resection was
achieved in six (85.7%) patients.
Table 1 Patient Characteristics, Treatment, and Outcome
Patient (age,
sex)
Side/Year/
Histology
Previous treatment Resection
status
Adjuvant
treatment
Recurrence site Outcome, follow-up
1 (34, F) Rt/2005/B1+B2 None Complete None Peritoneum 13 mo DOD, 25 mo
2 (58, M) Rt/2005/B2 S/adjuvant RT (54Gy) Complete None None Dead, pneumonia, 27
mo
3 (35, M) Rt/2006/B2+B3 S (sternotomy, stage
III)
Complete CT (CAP) None NED, 40 mo
4 (65, F) Lt/2007/B2 CT (CAV #2, VIP #10) Incomplete CT+RT (60Gy) Mediastinum,
pleura
DOD, 31 mo
5 (49, F) Lt/2007/B1+B2 CT (docetaxel,
cisplatin)
Complete CT (CAP) None NED, 27 mo
6 (50, M) Rt/2007/B2+B3 CT (docetaxel,
cisplatin)
Complete CT (CAP) None NED, 24 mo
7 (52, M) Lt/2008/B3 CT (docetaxel,
cisplatin)
Complete CT (CAP) None NED, 13 mo
DOD, dead of disease; NED, no evidence of disease;
S, surgery; RT, radiotherapy; CT, chemotherapy;
CAP, cyclophosphamide, doxorubicin, cisplatin; CAV, cyclophosphamide, doxorubicin, vincristine;
VIP, etoposide, ifosfamide, cisplatin.
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Patient 1
A 38-year-old woman presented with the superior vena
c a v a( S V C )s y n d r o m e .A b o u ta n1 1c ms i z e dt h y m o m a
with right pleural dissemination invaded the SVC. With-
out induction chemotherapy, en bloc extended total thy-
mectomy and a right EPP with SVC reconstruction was
performed via a posterolateral thoracotomy. This patient
had no neoadjuvant chemotherapy because she was a
young patient and especially had manifested sympto-
matic SVC syndrome. In addition, it was difficult to pre-
dict the effect of neoadjuvant chemotherapy, therefore
we performed surgery first and decided to discuss about
the necessity of adjuvant chemotherapy. The patient had
a satisfactory recovery. However, recurrence was found
in the abdominal cavity 13 months after the en bloc
resection. The patient refused systemic therapy and died
of disease progression 25 months after surgery.
Patient 2
A 62-year-old man underwent a video assisted thoraco-
scopic (VATS) thymectomy (Masaoka stage II, WHO
B2, mass size 5.3 cm) followed by adjuvant radiotherapy
(54Gy). Fifty five months post surgery, pleural recur-
rence developed and a right EPP was performed. The
patient recovered uneventfully. However, he died due to
pneumonia caused by cerebral infarction 27 months
post surgery.
Patient 3
A 39-year-old man underwent thymectomy via a median
sternotomy (Masaoka stage III, WHO B2+B3) at another
hospital. One year after the operation, the patient was
referred to this hospital because he had pleural seeding
with invasion of the right atrial wall. A right EPP with
partial resection and primary closure of the right atrial
wall was performed and then followed by adjuvant che-
motherapy (4 cycles). The patient was alive without
recurrence at 40 months after the EPP.
Patient 4
A 68-year-old woman who was diagnosed with a stage
IVA thymoma received chemotherapy (12 cycles) at a
different hospital. The patient was referred to this hospi-
tal for a chemoresistant tumor. An en bloc extended
total thymectomy and Left EPP were performed. Resi-
dual tumor around the innominate vein was left in place
because of tight adherence. The patient received adju-
vant chemoradiotherapy. However, she died of disease
progression 31 months after surgery.
Patient 5, 6 and 7
The most recent three patients that had mediastinal thy-
momas with pleural dissemination at initial presentation
were enrolled and received a standardized multidisci-
plinary approach to treatment. All patients had induc-
tion chemotherapy (3 cycles) followed by en bloc
extended total thymectomy with EPP and then adjuvant
chemotherapy (3 or 4 cycles). All of these patients are
still alive without any recurrences.
The median survival was 30.6 months and the Kaplan-
Meier 2-year survival was 100% (95% confidence inter-
val: 24.6-36.6 months). However, among the three
patients that were followed for over three years, one
patient died of distant metastasis in the abdominal cav-
ity, another patient died of pneumonia, and the other is
alive without disease recurrence. The survival curve is
shown in Figure 1.
Discussion
An 11 year (1995-2005) experience with thymic epithe-
lial tumors was previously reported [8]. The 5-year sur-
vival rate for a Masaoka stage IV (including IVA and
IVB) thymoma was only 52%, which is significantly
lower compared to stages I (96%), II (100%) and III
(71%) tumors. The complete resection rate was also low
(26.3%) for stage IV thymomas compared to stages I
(100%), II (100%) and III (85.3%) tumors. The reason for
the poor prognosis of stage IV thymomas was incom-
plete resections. Despite the fact that complete resection
has been identified as a prognostic factor associated
with long term survival of patients [9,10], few studies
have been carried out in patients with stage IVA thymo-
mas due to the difficulty of achieving a total resection,
its rare occurrence and its indolent natural history.
Stage IVA patients can be treated with primary che-
motherapy, radiotherapy [11] or chemoradiotherapy [12]
without surgical resection, as well as debulking surgery
with adjuvant radiation [13]. Although several investiga-
tors have attempted to improve the survival of patients
with locally advanced thymoma, the data has been
inconsistent with regard to the response rate and survi-
val. Our approach is with aggressive surgery to eradicate
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Figure 1 Overall survival in the 7 patients that underwent EPP
for stage IVA thymoma.
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extensive pleural dissemination, should be treated; in
these cases, complete resection is not possible by simple
parietal pleurectomy and lung preserving surgery. The
most reliable resection method for stage IVA thymomas
might be the EPP; because this procedure can remove
invisible tumor cells as well as all gross implants.
Recent studies have reported favorable experiences
with the EPP for cure of stage IVA thymomas [14-16].
The EPP for stage IVA thymomas has been performed
at this hospital since 2005. This series had no cardiore-
spiratory morbidities, no perioperative death, and a rea-
sonable hospital stay. These favorable results may be
due to relatively young patients, with a good perfor-
mance status and no underlying pulmonary disease in
addition to the meticulous postoperative care.
Wright and colleagues [14] carried out EPP in five
stage IVA patients. The five-year survival rate was
reported to be 75% and was 50% for 10-years, which
was fairly good compared to previous reports. Ishikawa
and colleagues [16] reported 11 patients with invasive
thymomas disseminated into the pleural cavity that
underwent multimodality therapy. The patients that
underwent EPP (n = 4) had better local recurrence free
survival compared to the patients that did not have an
EPP (n = 7) (5-year: 75% vs. 16%, 10-year: 75% vs. 0%).
Huang and colleagues [15] reported on multimodality
therapy in 18 patients with stage IVA thymomas. Com-
plete resections were performed in 12 patients including
nine pleurectomies and three EPP procedures. Among
three out of the nine patients with pleurectomies, recur-
rences developed in the pleura. By contrast, three
patients that underwent an EPP were alive without dis-
ease recurrence at 4, 32, and 112 months. These results
suggest that the EPP achieves a higher complete local
control rate than other surgical procedures. Among the
completely resected patients in this series, distant metas-
tases developed in one patient, who was the first EPP
case at this hospital, and had no systemic therapy. After
this experience, systemic therapy for stage IVA thymo-
mas became an important part of treatment.
Many studies suggest a multimodality approach may
lower the recurrence rate and increase the resectability
of advanced thymomas and this approach is currently
widely accepted [6,7,15,17]. However, how to combine
these modalities remains controversial in patients with
stage IVA thymomas. We concluded that an optimal
treatment sequence for stage IVA thymomas might
include induction chemotherapy, en bloc extended total
thymectomy with EPP, and adjuvant chemotherapy. The
three most recent consecutive patients (patients 5, 6 and
7) were treated by the protocol discussed above. They
received the same chemotherapy agents (doxetaxel and
cisplatin) for induction chemotherapy and they all had a
partial response. Complete resection was performed by
an en bloc extended total thymectomy and EPP. Adju-
vant chemotherapy included CAP (cyclophosphamide,
doxorubicin and cisplatin), and all the patients are cur-
rently alive without diseaser e c u r r e n c e .T h ep a t i e n t s
that were planned to have EPP did not receive preopera-
tive radiotherapy. Preoperative radiotherapy may have
adverse effects on the postoperative outcomes because it
can damage the heart and lungs with the wide extent of
the radiation field needed for treatment. Radiotherapy
was performed in only one patient with macroscopic
residual tumor around the innominate vein. Hemithor-
acic radiation was not carried out in this series. All of
the patients that received adjuvant chemotherapy alone
(n = 4) had no recurrence. Huang and colleagues [15]
treated four patients with induction chemotherapy fol-
lowed by EPP and then adjuvant hemithoracic radiation
for stage IVA thymomas. Wright [14] suggested induc-
tion chemotherapy followed by EPP, and then adjuvant
chemoradiation. However, further study of the role of
adjuvant chemotherapy or radiotherapy is needed.
En bloc extended total thymectomy and EPP was per-
formed with extended incision of a posterolateral thora-
cotomy. During the surgery, meticulous attention was
needed to prevent droplet metastasis. In order to pre-
vent tumor cell spillage, black silk 3-0 sutures were used
immediately when tearing of the parietal pleura
occurred during extrapleural dissection. In two cases
(patients 5 and 7) requiring resection of the innominate
vein, a median sternotomy followed the posterolateral
thoracotomy. Performing a posterolateral thoracotomy
followed by a median sternotomy will lessen the risk for
pleural droplet metastasis in the opposite thoracic cav-
ity. If EPP is performed after opening the opposite
pleura, gravity may enhance the possibility of droplet
metastasis on the opposite side.
Selection criteria for the EPP must be considered. First,
the patient’s functional status has to be good enough to
tolerate the pneumonectomy. Second, there should be no
metastatic disease in the opposite thorax or the extrathor-
acic cavity. In this series, the PET-CT was used to rule out
distant metastases. Third, complete or nearly complete
resection should be expected when performing an EPP.
Otherwise, a palliative approach should be considered in
inoperable cases. The CT has been used to examine tumor
invasion of neighboring organs, such as the heart, great
vessels, and chest wall. Usually, the innominate vein and
the superior vena cava can be safely resected. For patient
7, preparations were made for cardiopulmonary bypass
because of concerns about aortic arch invasion. Fortu-
nately, there was no need for aortic arch replacement;
aortic invasion was not considered an absolute contraindi-
cation to the procedure. Forth, if a limited resection can
achieve a complete resection, in individual pleural and
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it is most effective.
In this series, the outcome of extrapleural pneumo-
nectomy was favorable with low morbidity and no mor-
tality. However, the follow-up duration for this study
was comparatively short for assessment of late recur-
rence and long term survival. In the future, multicenter
trials are needed to establish standard treatment using a
multimodality therapy including surgical procedures.
Conclusions
En bloc extended total thymectomy and extrapleural
pneumonectomy was safe and effective in selected
patients with Masaoka stage IVA thymomas and can be
expected to achieve complete local control. Although
the treatment strategy has yet to be standardized, com-
plete resection with appropriate systemic therapy should
improve survival in an otherwise fatal disease.
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